What if you could run your clinical trial before running your clinical trial? Pharma CMOs and clinical development leads: that question should stop you cold. More than 90% of drugs that enter clinical trials fail. Three out of four of those failures come down to efficacy and safety, meaning the drug just did not work or was not safe. And by the time you find out, you have already burned years and hundreds of millions of dollars. QuantHealth just raised $45M in Series B funding to change that math. 🧬 Here is who they are and what they built. Founded in 2020 by CEO Orr Inbar and Chief Strategy and Operations Officer Arnon Horev, QuantHealth built an AI platform that ...

CMS just proposed the most disruptive radiology payment shift in years. 🚨 Site-neutral imaging payments are coming for hospital outpatient departments. If you run, bill for, or contract with an outpatient imaging program, you need to understand what changed. Here is the framework. THE CY 2027 SITE-NEUTRAL IMAGING FRAMEWORK (Based on the CMS CY 2027 OPPS Proposed Rule, summarized by the ACR) 1. WHAT IS CHANGING CMS proposed expanding site-neutral payment to noncontrast imaging services furnished in excepted off-campus provider-based departments (PBDs). These are the grandfathered hospital outpatient departments protected under Section 603 of the Bipartisan Budget Act of 2015. They have been billing at higher OPPS rates for years. That protection is now being challenged. 2. WHICH IMAGING SERVICES ...

The waiting room is full. It has never been this full. 🏥 It is National Health Center Week, and the numbers just landed. According to xtelligent Patient Engagement, HRSA-funded health clinics treated 32.7 million patients in 2025. That is a historic high for the 61-year-old Health Center Program. Up more than 350,000 patients from 2024. And the NACHC figure is even bigger: 1 in 7 Americans now receives care from a community health center. That includes 1 in 3 in rural America. One year ago that number was 1 in 10. Let that sink in. Those 52.3 million patients are being seen by 340,000 healthcare professionals working across 1,526 CHCs in 17,400 communities. These are not abstract policy numbers. That ...

AI just stopped flagging findings. It started writing the report. 🖊️ That is a different product category entirely. The consensus right now is that radiology AI is a detection layer. A flag. A second pair of eyes sitting beside the radiologist, handing them a score. The industry has spent a decade building that story. Here is my read: that framing is already obsolete. In July 2026, the FDA granted 510(k) clearance to DeepHealth Breast Ultrasound, the commercial name for the See-Mode Augmented Reporting Tool, Breast, or SMART-B. According to Discoveries in Health Policy, the system performs automated lesion detection and characterization and generates radiology report findings and impressions, while leaving final assessment under radiologist control. This is not a detection ...

Most lung cancer AI detects nodules. That is not the hard part. 🫁 The hard part is telling the radiologist which one is probably cancer, right now, not after three to six months of watchful waiting. This week, Eyonis and Canon Medical Systems' Olea Medical announced a strategic commercial agreement to expand U.S. access to eyonis LCS, according to Globe Newswire. Here is why this matters more than a typical distribution deal. 📌 The consensus is that detection AI is the finish line. Find the nodule. Flag the abnormality. Hand it to the radiologist. Done. My read: detection alone is actually where the dangerous ambiguity begins. 🔍 The evidence tells a different story. eyonis LCS is described as the first ...

$8.049 billion. That is what CMS is paying out in uncompensated care in FY 2027. 🏥 That number alone tells you how much structural weight hospitals are already carrying before a single new mandate kicks in. On July 31, 2026, CMS issued the FY 2027 Inpatient Prospective Payment System final rule. According to the National Law Review, it is scheduled for Federal Register publication on August 4, 2026. And it is packed with changes that every hospital finance, compliance, and strategy team needs to know right now. Save this post. Here is the breakdown. BEFORE vs. AFTER: THE RULE THAT CHANGED THE MOST Old rule: FDA breakthrough device designation or qualified infectious disease product (QIDP) status gave manufacturers an alternative ...

A simple stool test, offered every 2 years, cut colon cancer deaths in half. 🧬 That is not a headline from a clinical trial in a controlled setting. That is what happened in the real world, over 21 years, across 2.2 million people. According to Petra, the Jordan News Agency reporting on a study published August 5, 2026, the Basque Country's colorectal cancer screening program cut mortality among adults aged 50 to 69 by 50.1 percent. Mortality dropped from 39.7 to 19.8 deaths per 100,000 people. Without the program, researchers estimated mortality in that age group would have been 46.2 percent higher. The tool was not a colonoscopy. It was FIT, the Fecal Immunochemical Test, a non-invasive method that detects ...

Last week in healthcare funding moved serious money across 10 deals. 💰 From metastatic cancer to provider credentialing to youth mental health, the breadth was notable. Here is every deal I could verify: 🔹 AdvanCell, $315M, Series D. Advancing ADVC001, a Lead-212 PSMA-targeted radioligand therapy for metastatic prostate cancer toward Phase 3. The round was oversubscribed and upsized. 🔹 Beeline Medicines, $126.3M, Series A extension, bringing total Series A to $426.3M. Developing a portfolio of highly selective therapeutic candidates targeting the underlying causes of immune-mediated diseases including lupus and atopic dermatitis. 🔹 RQ Bio, $115M, Series A. Advancing RQB01, designed to deliver broad protection against influenza through a dual mechanism of action targeting conserved epitopes. Round described as oversubscribed. 🔹 ...

Last week in healthcare funding moved serious money across 10 deals. 💰 From metastatic cancer to provider credentialing to youth mental health, the breadth was notable. Here is every deal I could verify: - AdvanCell, $315M, Series D. Advancing ADVC001, a Lead-212 PSMA-targeted radioligand therapy for metastatic prostate cancer toward Phase 3. According to Diagnostics World News, the round was oversubscribed and upsized. - Beeline Medicines, $126.3M, Series A extension, bringing total Series A to $426.3M. Developing a portfolio of highly selective therapeutic candidates targeting the underlying causes of immune-mediated diseases including lupus and atopic dermatitis. Source: Diagnostics World News, July 29. - RQ Bio, $115M, Series A. Advancing RQB01, designed to deliver broad protection against influenza through a dual ...